Predicta Biosciences
Latest round
- Series A
Last raised
- Oct 2025
Total raised
- $23M
Investors
- 7
About Predicta Biosciences
Founded in 2023, Predicta Biosciences, Inc. specializes in molecular diagnostics, particularly for oncology. The founder's background is not detailed, and there are no records of prior companies.Predicta Biosciences specializes in advanced diagnostic solutions, primarily through its flagship product, GenoPredicta™, which leverages whole genome sequencing (WGS) of cells obtained from both bone marrow and blood. This innovative platform provides unprecedented sensitivity and accuracy for the diagnosis of multiple myeloma and other plasma cell dyscrasias, significantly outpacing traditional methods such as fluorescence in situ hybridization (FISH). The GenoPredicta™ technology enables the detection of critical genomic alterations, including single nucleotide variants (SNVs) and small insertions/deletions (InDels), essential for understanding disease prognosis and therapeutic response. By facilitating routine blood monitoring, Predicta aims to empower healthcare providers with essential insights for timely disease intervention and management.Predicta Biosciences generates revenue through its B2B model, catering to healthcare providers and institutions that require advanced diagnostic tools for blood cancers and autoimmune diseases. The company's flagship product, GenoPredicta™, is sold directly to healthcare facilities, enabling physicians to order tests that provide comprehensive genomic data for patient management. The pricing structure for GenoPredicta™ reflects its advanced technological capability and the value it brings to clinical practice, though specific pricing details are proprietary. By offering molecular diagnostic services that include minimal residual disease (MRD) detection and genomic characterization at the single-cell level, Predicta facilitates ongoing patient monitoring and therapeutic decision-making, enhancing its appeal within the oncology and hematology markets. In October 2025, Predicta Biosciences, Inc. Predicta aims to launch new products targeting additional blood cancer diagnostics and to expand its market reach, although specific geographic regions and product details have not been disclosed.
Who invested in Predicta Biosciences
7 investors across 1 round
See all investors in Predicta Biosciences
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Oct 9, 2025
Amount
$23M
Investors
Questions about Predicta Biosciences
Who invested in Predicta Biosciences?
Predicta Biosciences has 7 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Predicta Biosciences raised?
Predicta Biosciences has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Predicta Biosciences last raise money?
Predicta Biosciences's most recent round on record is a Series A, in Oct 2025.
What does Predicta Biosciences do?
Founded in 2023, Predicta Biosciences, Inc.
Where is Predicta Biosciences headquartered?
Predicta Biosciences is headquartered in Cambridge, US.
Which VCs invest in companies like Predicta Biosciences?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Predicta Biosciences's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Predicta Biosciences? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.